Crispr Therapeutics and partner Vertex Pharmaceuticals said on Monday morning that the first patient in a trial using CTX001 received the one-time medicine.
from RSS Feeds : RSS Feed - NDTV Gadgets360.com https://ift.tt/2XjoJ5n
Ut wisi enim ad minim veniam, quis nostrud exerci tation ullamcorper suscipit lobortis nisl ut aliquip ex ea commodo consequat. Duis autem vel eum iriure dolor in hendrerit in vulputate velit esse molestie consequat.
0 Comments